More News! For those who want to keep up with everything

amoeba biocontol rust disease agriculture

More News! 4 Jul 2019

First Eco-Friendly Treatment Stops Fungal Crop Disease

An eco-friendly antifungal treatment developed by the French biotech Amoéba has reduced rust infections in legumes by 85% in a recent field trial. Rust is a plant disease caused by fungi that is very hard to treat. Although chemical fungicides can be used against it, these are often expensive and harmful to other organisms, including […]

July 4, 2019 - 3 minutesmins - By Jonathan Smith

More News! 27 Jun 2019

German Biotech Will Target Parkinsonian Disorders with €12M Series A

Modag has developed a candidate drug targeting the neurodegenerative disease multiple system atrophy, which it plans to take to the clinic with €12M in Series A funds. Multiple system atrophy is a rare disorder, with similar symptoms to Parkinson’s disease, that is caused by breakdown of neurons in parts of the brain. The German biotech’s […]

June 27, 2019 - 2 minutesmins - By Helen Albert

More News! 26 Jun 2019

Carbios Raises €14.5M to Build Plant to Make 100% Recycled Plastic

The French bioplastics biotech Carbios has raised €14.5M through a placing of shares in order to fund the construction of a demonstration plant that will use enzymes to make 100% recycled plastics. Around 75% of the proceeds will fund the demonstration plant, which is due to be fully operational by the end of next year. […]

June 26, 2019 - 2 minutesmins - By Jonathan Smith

evotec tuberculosis treatment gates foundation

More News! 12 Jun 2019

Evotec to Reduce the Burden of Tuberculosis Treatment with €21M Grant

The Bill and Melinda Gates Foundation has granted the German biotech Evotec €21M ($23.8M) to discover drug combinations that can reduce the duration of tuberculosis treatment, which normally takes over six months. Evotec will use the money to test different drug combinations for tuberculosis in the preclinical stage. The partnership will last for five years, […]

June 12, 2019 - 2 minutesmins - By Jonathan Smith

inflarx trial inflammatory disease fail skin

More News! 6 Jun 2019

Shares Drop 90% as Antibody for Inflammatory Skin Disease Fails Phase II

The German company InflaRx has seen its shares on the Nasdaq plummet after announcing that its treatment for an inflammatory skin disease failed to beat the placebo in a phase IIb trial. The trial had enrolled 179 patients with hidradenitis suppurativa, an incurable condition causing painful lumps on the skin. By the 16th week of […]

June 6, 2019 - 2 minutesmins - By Jonathan Smith

nanobiotix nanotechnology nanoparticle cancer

More News! 28 May 2019

Nanomedicine Company Launches in France to Improve Drug Safety

The French nanomedicine biotech Nanobiotix is spinning out a subsidiary company developing nanoparticles that can enhance a drug’s effectiveness and decrease side effects. Called Curadigm, the spinout will be developing nanotechnology with the potential to make low drug doses more effective at treating different conditions, which could make treatments cheaper and with fewer side effects […]

May 28, 2019 - 2 minutesmins - By Jonathan Smith

More News! 24 May 2019

French Pharma Acquires Israeli Microalgae Biotech

The French pharmaceutical manufacturer Solabia has acquired the Israeli biotech Algatech, which grows microalgae to produce bio-sourced food additives. The financial details of the acquisition were undisclosed. The incoming financial backing from Solabia will fuel the expansion of Algatech’s manufacturing muscle and research programs, which are based in the deserts of Israel. The acquisition represents […]

May 24, 2019 - 2 minutesmins - By Jonathan Smith

More News! 23 May 2019

Irish Life Sciences VC Raises €118M Fund with European Focus

Fountain Healthcare Partners has raised €118M in its third fund dedicated to investing in life sciences, with the majority of the funds destined to go to European companies. Of the total raised, €45M was contributed by the European Investment Fund, which invested in both of Fountain’s previous funds. Other investors are Coolidge Limited, the Ireland […]

May 23, 2019 - 2 minutesmins - By Clara Rodríguez Fernández

More News! 16 May 2019

Israeli Startup Raises €11M to Become the First to Sell Lab-Grown Steaks

Aleph Farms has closed a Series A round of €10.7M ($12M) to beef up its manufacturing and get its lab-grown steaks into the market within the next four years. Aleph Farms is the first company to have created a lab-grown beef steak, which was publicly tasted last December. With the money raised, the company aims […]

May 16, 2019 - 2 minutesmins - By Jonathan Smith

dna synthesis synthetic biology cambridge

More News! 16 May 2019

UK Scientists Open Bacterial Genome Up to Making Artificial Proteins

A research group from the University of Cambridge has created bacteria with less complexity in their genome, which could free up DNA code for producing synthetic proteins never before seen in nature. There are lots of redundancies in the DNA code, meaning there is sometimes more than one DNA sequence that can result in the […]

May 16, 2019 - 2 minutesmins - By Jonathan Smith

achondroplasia pfizer therachon acquisition

More News! 9 May 2019

Pfizer Pays up to €700M to Acquire Swiss Biotech Restoring Bone Growth in Achondroplasia

Pharma giant Pfizer is acquiring the Swiss biotech Therachon, which is developing a protein drug to boost bone growth in the genetic condition achondroplasia. Pfizer will pay €303M ($340M) upfront, and up to €420M ($470M) dependent on Therachon reaching milestones in the development of its drug improving bone growth in achondroplasia. This genetic condition inhibits […]

May 9, 2019 - 2 minutesmins - By Jonathan Smith

More News! 16 Apr 2019

Researchers in Israel 3D Print a Personalized Heart from Donor’s Tissue

A group of scientists in Israel is the first to 3D print a vascularized heart using reprogrammed cells and biological material from a donor. The technology could one day provide printed hearts for transplants with low risks of rejection by a patient’s immune system. Organ bioprinting is a technique similar to 3D printing where you […]

April 16, 2019 - 3 minutesmins - By Jonathan Smith

Resources

Categories

The twelve hottest biotech companies in the Boston area

Biotech bankruptcies: what to expect in 2024 following a record year?

Approaches

Therapeutic areas

RNA editing set to take off: could it outperform gene editing?

Future of cancer treatment: what will therapy look like in 2034?

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us